{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:22:22Z","timestamp":1780554142952,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.vaccine.2012.09.059","type":"journal-article","created":{"date-parts":[[2012,10,3]],"date-time":"2012-10-03T18:00:43Z","timestamp":1349287243000},"page":"6971-6979","source":"Crossref","is-referenced-by-count":45,"title":["Adjuvants and inactivated polio vaccine: A systematic review"],"prefix":"10.1016","volume":"30","author":[{"given":"Jennifer","family":"Hawken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Troy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.09.059_bib0005","unstructured":"Data and monitoring polio this week; 2012. Available from: http:\/\/www.polioeradication.org\/Dataandmonitoring\/Poliothisweek.aspx [accessed 01.07.12]."},{"key":"10.1016\/j.vaccine.2012.09.059_bib0010","unstructured":"Zehrung D, Hickling J, Jones R, Nundi N. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries: an economic analysis of strategies to reduce the cost of routine IPV immunization; 2010. Available from: http:\/\/www.path.org\/publications\/details.php?i=1809 [accessed 01.07.12]."},{"key":"10.1016\/j.vaccine.2012.09.059_bib0015","first-page":"213","article-title":"Polio vaccines and polio immunization in the pre-eradication era: WHO position paper","volume":"85","year":"2010","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/aje\/kwq320","article-title":"From emergence to eradication: the epidemiology of poliomyelitis deconstructed","author":"Nathanson","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1006\/biol.1993.1096","article-title":"Genetic basis of attenuation of the Sabin oral poliovirus vaccines","author":"Minor","year":"1993","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biologicals.2006.02.005","article-title":"Vaccine-derived poliovirus from long term excretors and the end game of polio eradication","author":"Martin","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0035","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1056\/NEJMoa0910074","article-title":"Implications of a circulating vaccine-derived poliovirus in Nigeria","author":"Jenkins","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.vaccine.2011.11.018","article-title":"Intradermal fractional dose inactivated polio vaccine: a review of the literature","author":"Nelson","year":"2012","journal-title":"Vaccine"},{"issue":"May\u2013June (9\u201310)","key":"10.1016\/j.vaccine.2012.09.059_bib0045","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0264-410X(97)00293-4","article-title":"Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine","volume":"16","author":"Nirmal","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0050","series-title":"Dose optimization strategies for vaccines: the role of adjuvants and new technologies","author":"Dekker","year":"2008"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0055","series-title":"Vaccines","first-page":"605","article-title":"Poliovirus vaccine \u2013 inactivated","author":"Plotkin","year":"2008"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0060","series-title":"Vaccines","first-page":"631","article-title":"Poliovirus vaccine \u2013 live","author":"Sutter","year":"2008"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0065","series-title":"Vaccines","first-page":"59","article-title":"Immunologic adjuvants","author":"Vogel","year":"2008"},{"issue":"January\u2013February","key":"10.1016\/j.vaccine.2012.09.059_bib0070","first-page":"70","article-title":"Serological response of guinea pigs to inoculation with anti-poliomyelitis vaccine containing adjuvant substances","volume":"35","author":"Picciotto","year":"1960","journal-title":"Riv Ist Sieroter Ital"},{"issue":"August","key":"10.1016\/j.vaccine.2012.09.059_bib0075","first-page":"646","article-title":"On the problem of antibody formation against poliomyelitis in small children. Studies on the effect of an adjuvant vaccine with antigen components against poliomyelitis, diphtheria, pertussis and tetanus","volume":"110","author":"Auerswald","year":"1960","journal-title":"Wien Med Wochenschr"},{"issue":"January","key":"10.1016\/j.vaccine.2012.09.059_bib0080","first-page":"44","article-title":"Immunogenic activity of aqueous and aluminum oxide adsorbed poliovirus vaccine in Macaca mulatta","volume":"75","author":"Henneberg","year":"1962","journal-title":"Am J Hyg"},{"issue":"May (3)","key":"10.1016\/j.vaccine.2012.09.059_bib0085","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/oxfordjournals.aje.a120703","article-title":"Further investigations on the immunogenic activity of aqueous and aluminum oxide adsorbed inactivated poliovirus vaccines in Macaca mulatta","volume":"85","author":"Drescher","year":"1967","journal-title":"Am J Epidemiol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.09.059_bib0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0166-0934(85)90102-8","article-title":"The immune response to poliovirus specific synthetic peptides: effects of adjuvants and test animal species","volume":"10","author":"Emini","year":"1985","journal-title":"J Virol Methods"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2012.09.059_bib0095","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/00006454-200110000-00011","article-title":"Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants","volume":"20","author":"Yeh","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"February (10)","key":"10.1016\/j.vaccine.2012.09.059_bib0100","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.vaccine.2010.12.103","volume":"29","author":"Li","year":"2011","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.09.059_bib0105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1542\/peds.2007-3317","article-title":"Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial","volume":"123","author":"Guerra","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0169-409X(98)00008-8","article-title":"Aluminum compounds as vaccine adjuvants","author":"Gupta","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0115","first-page":"131","article-title":"Preparation and use of calcium phosphate-adsorbed vaccines","volume":"65","author":"Relyveld","year":"1986","journal-title":"Dev Biol Stand"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2012.09.059_bib0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/biol.1994.1008","article-title":"Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid","volume":"22","author":"Gupta","year":"1994","journal-title":"Biologicals"},{"issue":"November (6)","key":"10.1016\/j.vaccine.2012.09.059_bib0125","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/CDLI.7.6.899-903.2000","article-title":"Calcium phosphate nanoparticle adjuvant","volume":"7","author":"He","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2012.09.059_bib0130","first-page":"739","article-title":"Simultaneous tetanus and poliomyelitis vaccination of infants in a tropical environment","volume":"55","author":"Sureau","year":"1977","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.vaccine.2012.09.059_bib0135","first-page":"41","article-title":"Rational method of producing sera with high titers of virus neutralizing antibodies","author":"Kravchenko","year":"1977","journal-title":"Zh Mikrobiol Epidemiol Immunobiol"},{"issue":"July (3)","key":"10.1016\/j.vaccine.2012.09.059_bib0140","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3181\/00379727-74-17964","article-title":"Formation of neutralizing antibody in monkeys injected with poliomyelitis virus and adjuvants","volume":"74","author":"Ward","year":"1950","journal-title":"Proc Soc Exp Biol Med"},{"issue":"September (2)","key":"10.1016\/j.vaccine.2012.09.059_bib0145","first-page":"157","article-title":"The use of adjuvants to facilitate studies on the immunologic classification of poliomyelitis viruses","volume":"54","author":"Salk","year":"1951","journal-title":"Am J Hyg"},{"issue":"September\u2013October","key":"10.1016\/j.vaccine.2012.09.059_bib0150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0021-8707(63)90005-4","article-title":"Poliovirus vaccines in mineral oil adjuvant. I. Animal toxicity and serologic response data","volume":"34","author":"Hilleman","year":"1963","journal-title":"J Allergy"},{"issue":"September\u2013October","key":"10.1016\/j.vaccine.2012.09.059_bib0155","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/0021-8707(63)90006-6","article-title":"Poliovirus vaccines in mineral oil adjuvant. II. Clinical reaction and antibody response","volume":"34","author":"Stone","year":"1963","journal-title":"J Allergy"},{"issue":"May\u2013June","key":"10.1016\/j.vaccine.2012.09.059_bib0160","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0021-8707(62)90086-2","article-title":"Use of poliomyelitis virus vaccine in light mineral oil adjuvant in a community immunization program and report of reactions encountered","volume":"33","author":"Cutler","year":"1962","journal-title":"J Allergy"},{"issue":"January (4)","key":"10.1016\/j.vaccine.2012.09.059_bib0165","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.vaccine.2010.11.043","article-title":"Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions","volume":"29","author":"Baldwin","year":"2011","journal-title":"Vaccine"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.09.059_bib0170","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/14712591003724662","article-title":"MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk","volume":"10","author":"Durando","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2012.09.059_bib0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0264-410X(98)90039-1","article-title":"Immunological activity of chitin and its derivatives","volume":"2","author":"Nishimura","year":"1984","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2012.09.059_bib0180","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00705-008-0047-4","article-title":"Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines","volume":"153","author":"Ghendon","year":"2008","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0185","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/jmv.22030","article-title":"Chitosan as an adjuvant for poliovaccine","volume":"83","author":"Ghendon","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1477-3155-9-55","article-title":"Biodegradable nanoparticles are excellent vehicle for site directed in vivo delivery of drugs and vaccines","volume":"9","author":"Mahapatro","year":"2011","journal-title":"J Nanobiotechnol"},{"issue":"April (3)","key":"10.1016\/j.vaccine.2012.09.059_bib0195","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.yrtph.2009.09.015","article-title":"The safety of chitosan as a pharmaceutical excipient","volume":"56","author":"Baldrick","year":"2010","journal-title":"Regul Toxicol Pharmacol"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2012.09.059_bib0200","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1078-0432.CCR-05-1730","article-title":"Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166\/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma","volume":"12","author":"Kim","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2012.09.059_bib0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/jcb.240490106","article-title":"Immunomodulatory role of 1,25-dihydroxyvitamin D3","volume":"49","author":"Lemire","year":"1992","journal-title":"J Cell Biochem"},{"issue":"April (15\u201316)","key":"10.1016\/j.vaccine.2012.09.059_bib0210","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0264-410X(98)00476-9","article-title":"Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers","volume":"17","author":"Kriesel","year":"1999","journal-title":"Vaccine"},{"issue":"February (4)","key":"10.1016\/j.vaccine.2012.09.059_bib0215","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1086\/499970","article-title":"1,25-Dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice","volume":"193","author":"Ivanov","year":"2006","journal-title":"J Infect Dis"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2012.09.059_bib0220","doi-asserted-by":"crossref","first-page":"686","DOI":"10.5694\/j.1326-5377.2010.tb03702.x","article-title":"Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting","volume":"192","author":"Hackman","year":"2010","journal-title":"Med J Aust"},{"issue":"April (6522)","key":"10.1016\/j.vaccine.2012.09.059_bib0225","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.09.059_bib0230","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"November (47)","key":"10.1016\/j.vaccine.2012.09.059_bib0235","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1016\/j.vaccine.2009.08.047","article-title":"CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus","volume":"27","author":"Yang","year":"2009","journal-title":"Vaccine"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2012.09.059_bib0240","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4049\/jimmunol.164.2.944","article-title":"Mechanism and function of a newly identified CpG DNA motif in human primary B cells","volume":"164","author":"Hartmann","year":"2000","journal-title":"J Immunol"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2012.09.059_bib0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/653112","article-title":"Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial","volume":"51","author":"Sogaard","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0250","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4615-1823-5_7","article-title":"A compendium of vaccine adjuvants and excipients","volume":"6","author":"Vogel","year":"1995","journal-title":"Pharm Biotechnol"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2012.09.059_bib0255","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0264-410X(86)90046-0","article-title":"Adjuvanticity of stearyl tyrosine on inactivated poliovirus vaccine","volume":"4","author":"Landi","year":"1986","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.09.059_bib0260","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.vaccine.2012.01.070","article-title":"Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens","author":"Watson","year":"2012","journal-title":"Vaccine"},{"issue":"June (1)","key":"10.1016\/j.vaccine.2012.09.059_bib0265","first-page":"25","article-title":"Comparison of the immune response against polio peptides covalently-surface-linked to and internally-entrapped in liposomes","volume":"9","author":"Tan","year":"1991","journal-title":"Asian Pac J Allergy Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T12:22:46Z","timestamp":1594729366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12013795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":53,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0264410X12013795"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.09.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}